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Abstract
Background: We showed that mast cells played a critical role in the progression of heart failure induced by
pressure overload and viral myocarditis in mice. In this study, we investigated the effect of cetirizine, a selective H1
receptor antagonist, on experimental viral myocarditis induced by encephalomyocarditis (EMC) virus.
Methods: Four-week-old inbred male DBA/2 mice were inoculated intraperitoneally with 10 plaque-forming units
(pfu) of the EMC virus. Cetirizine was administered orally at a dose of 1 or 10 mg/kg per day for the survival study,
and 1 mg/kg for the histologic and gene expression studies, beginning on the day of viral inoculation.
Results: Cetirizine improved survival dose dependently. Heart weight to body weight ratio was significantly
decreased in mice treated with cetirizine. The area of myocardial necrosis was significantly smaller in the hearts of
mice treated with cetirizine compared with controls. Gene expressions of tumor necrosis factor, interleukin 6, and
metalloproteinase 2 were significantly suppressed in the hearts of mice treated with cetirizine.
Conclusion: These results suggest that cetirizine exerts its beneficial effects on viral myocarditis by suppressing
expression of pro-inflammatory cytokines, genes related to cardiac remodeling in the hearts of mice.
Introduction
In recent years, mast cells have been implicated in the
pathogenesis of cardiovascular and atherosclerotic disor-
ders. In particular, we have observed that mast cells
cause apoptosis of cardiac myocytes and proliferation of
nonmyocytes in vitro [1]. Furthermore, myocardial hista-
mine and tryptase content, and mast cell density are
higher in heart failure due to idiopathic dilated or
ischemic cardiomyopathy than in control hearts [2]. We
showed that mast cells played a critical role in the pro-
gression of heart failure induced by pressure overload
and viral myocarditis in mice [3,4]. In our previous
study, mast cell deficient mice developed less pro-
nounced myocardial necrosis and cellular infiltration
induced by encephalomyocarditis virus, and the hista-
mine H1-receptor antagonist improved survival of mice
and in improved histological changes [4].
In the present study, we studied the effects of a hista-
mine H1-receptor antagonist, cetirizine on the expressions
of inflammatory cytokines and metalloproteinases on
experimental viral myocarditis induced by encephalomyo-
carditis (EMC) virus which play important roles in cardiac
remodeling.
Methods
Experimental myocarditis model
Stocks of the myocardiotrophic variant of EMC virus were
prepared as previously described [5,6], and stored at -80°C.
The 4-week-old male DBA/2 mice used in this study were
treated in accordance with local institutional guidelines at
all stages of the experiments. A total of 50 mice were
inoculated with 0.2 ml EMC virus in phosphate buffered
saline diluted to a concentration of 10 pfu/ml on day 0.
The histamine H1-receptor antagonist cetirizine was pur-
chased from Sigma (Tokyo, Japan). Cetirizine was dis-
solved in distilled water and given orally by gavage at a
dose of 1 or 10 mg/kg per day starting on the same day on
1o r1 0m g / k gp e rd a ys t a r t i n go nt h et h i r dd a ya st h e
EMC virus inoculation (each n = 10). Control mice were
given distilled water. For the histologic study, and the gene
expression study, the study groups were control (n = 10),
and cetirizine 1 mg/kg (n = 10). Control mice were given
0.2 ml of distilled water. At day 5, we observed that some
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been due to viremia and/or encephalitis. Surviving mice
were sacrificed by cervical dislocation at day 5 for the gene
expression study and at day 6 for the histopathologic
experiments. The hearts were dissected, immediately fro-
zen and stored at -80°C, and the section of interest fixed
in formalin.
Heart Weight and Lung Weight
Heart, lung and body weight were measured and the
heart and lung weight/body weight was calculated.
Histopathological examination
We examined the histopathologic changes on day 6. The
hearts were fixed in 10% formalin, and embedded in
paraffin. The left ventricles (LV) were sliced horizontally
to the long axis, and stained with hematoxylin - eosin,
and Masson’s trichrome for light microscopy examina-
tions. The extent of myocardial necrosis was evaluated
by measuring the ratio (%): myocardial necrosis area/
total LV area on a microscopic slide, using Microanaly-
sis (Ather Coporation, Tokyo, Japan), which can mea-
sure areas of different colors. We calculated the area of
myocardial necrosis, as indicated by the loss of red Mas-
son’s trichrome stain. Two investigators determined the
histologic score, which were averaged. The analyses
were blinded. To determine the number of mast cells,
the hearts were stained with toluidine blue. The total
number of mast cells in a given section (whole heart)
was calculated as cells/mm
2.
Assay of myocardial virus concentration
T e nm i c ef r o me a c ho ft h ec e t i r i z i n eo rc o n t r o lg r o u p
were sacrificed 6 days after EMCV virus inoculation.
Myocardial viral concentrations were determined only in
the sacrificed mice using an FL (human amnion cells)-
plaque assay and expressed as pfu/mg of myocardium as
described previously [7].
Quantitative reverse transcriptase polymerase chain
reaction analysis
A total of 18 of the 20 mice were studied for gene
expression. One mouse of the cetirizine 10 mg/kg group
and one control mouse died before day 5 and thus were
not appropriate for study because of post-mortem
changes.
Total RNA was isolated from the LV using the acid
guanidinium thiocyanate-phenol-chloroform method
and the RNA concentration was measured spectropho-
tochemically. First-strand cDNA was synthesized using
SUPERSCRIPT Preamplification System for First-Strand
cDNA Synthesis (GIBCO BRL). Real-time quantitative
PCR (TaqMan PCR) using an ABI PRISM 7700
Sequence Detection System and TaqMan PCR Core
Reagent Kit (Perkin-Elmer Corp, Foster City, CA) was
performed according to the manufacturer’sp r o t o c o l .
We used 2 μl of the First-strand cDNA, and the follow-
ing forward (F) and reverse (R) oligonucleotides, and
probes (P) were used for the quantification of tumor
necrosis factor (TNF) a, interleukin (IL)-6, and matrix
metalloproteinases (MMPs) 2and 9.
TNF-a F, 5′-CATCTTCTCAAAATTCGAGTGACAA;
TNF-a R, 5′-TGGGAGTAGACAAGGTACAACCC;
TNF-a P, 5′-CACGTCGTAGCAAACCACCAAGTG
GA;
IL-6F, Based on TaqMan produt No.4331348
IL-6R, Based on TaqMan produt No.4331348
IL-6P, Based on TaqMan produt No.4331348
Inducible Nitric Oxide Synthase (iNOS)
iNOSF, 5′- CAGCTGGGCTGTACAAACCTT-3′
iNOSR, 5′-CATTGGAAGTGAAGCGTTTCG-3′
iNOSP, 5′-CGGGCAGCCTGTGAGACCTTTGA-3′
MMP-2 F, 5′-ACTGACCTGCATGGAATCAGC-3′
MMP-2 R, 5′-GGTTACTTGAGTGTTCTAGCCCA-3′
MMP-2 P, 5′-TCTTTCTGGTGGCCGTGCATGA-3′
MMP-9 F, 5′-TTGTGGTCTTCCCCAAAGACC-3′
MMP-9 R, 5′-TATCCACCGAGCCATCTGTCTA-3′
MMP-9 P, 5′-AAAACCTCCAACCTCACGGACAC
CCA-3′
GAPDH F, 5′-TTCACCACCATGGAGAAGGC-3′;
GAPDH R, 5′-GGCATGGACTGTGGTCATGA-3′;
GAPDH P, 5′-TGCATCCTGCACCACCAACTGCT
TAG-3′.
The conditions for the TaqMan PCR were: 95°C for
10 min, followed by 40 cycles at 95°C for 15 s and 60°C
for 1 min.
Statistical analysis
The survival rate of mice was analyzed by the Kaplan-
Meier method, and survival differences between groups
were tested by the log-rank test. Statistical comparisons
of histological area and gene expressions were made by
the unpaired 2-tailed Student t test. All values are pre-
sented as mean ± SD. Differences were considered sta-
tistically significant at probability values < 0.05.
Results
Survival
Cetirizine improved survival dose dependently in mice
treated with 1 or 10 mg/kg compared with controls (p <
0.05, Figure 1). However, there was no significant differ-
ence in survival when cetirizine was started on the third
day (survived mice in cetirizine treated mice, n = 2 vs in
control, n = 1).
Heart weight and lung weight
Heart weight to body weight ratio was significantly
decreased in mice treated with cetirizine ([0.53 ± 0.06]
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-2, n = 9, mean ± SD) compared with controls
([0.68 ± 0.15] × 10
-2,n=9 ,p=0 . 0 1 ,F i g u r e2 A ) .L u n g
weight to body weight ratio was significant lower in
mice treated with cetirizine ([0.55 ± 0.12] × 10
-2,n=9 )
compared with controls ([0.67 ± 0.074] × 10
-2,n=9 ,
p = 0.02, Figure 2B).
Myocardial Histology
The area of myocardial necrosis on day 6 was signifi-
cantly less severe in the hearts of mice treated with
cetirizine 1 mg/kg (6.3 ± 0.3%) compared with controls
(17.3 ± 11.6%, p = 0.02) (Figure 3C). The area of necro-
sis was not improved when cetirizine was started on day
3 (15.6 ± 12.3, n = 8 vs Control 12.9 ± 4.4, n = 7, p =
0.59). Mast cell density did not show significant differ-
ence between cetirizine 1 mg/kg and control group
(0.80 ± 0.40, n = 9) vs (0.95 ± 0.64, n = 9, p = 0.6).
Myocardial viral concentration
Myocardial virus concentration on day 7 was (0.11 ±
0.02pfu/mg) in cetirizine treatment mice (n = 10) and
(0.13 ± 0.01pfu/mg, n = 10) in control mice (n = 10).
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Figure 1 Cetirizine improved survival dose dependently in mice treated with 1 or 10 mg/kg compared with controls (p < 0.05).
Figure 2 Effect of cetirizine on heart weight/body weight ratio (A), and lung weight/body weight (B) ratios in EMC viral myocarditis in
mice.
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(p < 0.05).
Gene Expressions
The gene expressions of TNF-a and IL-6, inflammatory
cytokines were significantly decreased compared with
controls (TNFa/GAPDH: 0.09 ± 0.12 vs 0.77 ± 0.59, p =
0.0038; IL-6/GAPDH: 12 ± 23 vs 56 ± 53, p = 0.0371;
each n = 9) in the hearts of mice treated with cetirizine
1 mg/kg (Figure 4A).
T h eg e n ee x p r e s s i o n so fM M P - 2 ,ak e ym o l e c u l ei n
cardiac remodeling, was significantly lower in the hearts
of mice treated with cetirizine compared with controls
(MMP-2/GAPDH: 0.07 ± 0.06 vs 0.3 ± 0.1, p < 0.0001;
Figure 4B). A trend for a reduction in MMP-9 was seen
(MMP/GAPDH: 0.14 ± 0.26 vs 0.5 ± 0.73, p = 0.19) in
the cetirizine group that did not reach statistical
significance.
The gene expressions of iNOS tended to be lower in
the cetirizine than in the control group, but the differ-
ences did not reach statistical significance (iNOS/
GAPDH: 0.114 ± 0.118 vs 0.920 ± 1.253, p = 0.073).
Discussion
In our model of EMC virus myocarditis, the number of
mast cells was increased on day 14 after EMC virus
inoculation, when myocardial fibrosis becomes apparent
[8], and in W/W
v and SI/Si
d strains of mice, we
observed that mast cell deficiency had beneficial effects
in the disorder.
We have reported that the gene expression of mast
cell chymase and tryptase was upregulated in the acute
phase of viral myocarditis and rose further in the suba-
cute phase of heart failure [8]. This activation coincided
with the development of myocardial necrosis and corre-
lated with the upregulation of MMP-9 and type-I pro-
collagen, suggesting that mast cell chymase and tryptase
participate in the acute inflammatory reaction as well as
the remodeling process associated with acute viral
myocarditis.
Evidence is growing that pro-inflammatory cytokines
play an important role in modulating cardiovascular
function and structure [9-11]. Arteriovenous IL-6 spil-
lover in the peripheral circulation increases with the
severity of heart failure, and an elevated level of plasma
IL-6 was a predictor of mortality in patients with heart
failure [12].
In the present study, cetirizine improved survival of
mice, congestion of the lungs, and myocardial necro-
sis, suppressed the expression of a pro-inflammatory
cytokines and decreased expression of MMP-2. Thus,
these may be the mechanisms by which cetirizine
Control Cetirizine 1mg/kg
x200
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x20
Control Cetirizine
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Figure 3 Effect of cetirizine on histopathology of mice hearts with EMC viral myocarditis. Representative pictures of the heart of mice
treated with 1 mg/kg of cetirizine and control mice. A. × 20. B. × 200. HE: Hematoxylin-eosin stain. MTC: Masson’s trichrome stain. C.
Quantitation of myocardial necrosis.
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gest that histamine releasedf r o mm a s tc e l l sm a yp l a y
a pivotal role in the pathogenesis of viral myocarditis.
However, antihistaminic agents, such as cetirizine, not
only act via mediation of H1 receptors, but may also
attenuate various steps in the inflammatory process.
A delay of three days after viral inoculation vastly
reduced its efficacy in reducing adverse responses to
viral myocarditis. Therefore, cetirizine should be
started as early as possible in treatment of viral
myocarditis.
Cetirizine has demonstrated several modulatory effects
on inflammatory responses. These effects included redu-
cing eosinophil migration induced by inflammatory
mediators in atopic and nonatopic adults, reducing the
expression of adhesion molecules associated with eosi-
nophil migration and adhesion of eosinophils to epithe-
lial cells and inhibiting the expression of various
pro-inflammatory cytokines and mediators in vitro and
in vivo [13].
A histamine H2 receptor block has been shown to be
beneficial in human heart failure [14]. We have shown
that mast cells stabilizer tranilast prevented development
of heart failure in an animal model of pressure overload
[3]. Therefore, not only H1 receptor blockers, but also
other agents which stabilize mast cells may have benefi-
cial effects on heart failure.
Although the exact molecular mechanisms of the ben-
eficial effect of cetirizine remains to be clarified,
cetirizine is a promising agent for the treatment of viral
myocarditis and merits further study.
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